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Abstract
Introduction: Cefepime has been associated with a greater risk of mortality than other beta-lactams in patients 
treated for severe sepsis. Hypotheses for this failure include possible hidden side-effects (for example, neurological) or 
inappropriate pharmacokinetic/pharmacodynamic (PK/PD) parameters for bacteria with cefepime minimal inhibitory 
concentrations (MIC) at the highest limits of susceptibility (8 mg/l) or intermediate-resistance (16 mg/l) for pathogens 
such as Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureus. We examined these issues in a 
prospective non-interventional study of 21 consecutive intensive care unit (ICU) adult patients treated with cefepime 
for nosocomial pneumonia.
Methods: Patients (median age 55.1 years, range 21.8 to 81.2) received intravenous cefepime at 2 g every 12 hours for 
creatinine clearance (CLCr) ≥ 50 ml/min, and 2 g every 24 hours or 36 hours for CLCr < 50 ml/minute. Cefepime plasma 
concentrations were determined at several time-points before and after drug administration by high-pressure liquid 
chromatography. PK/PD parameters were computed by standard non-compartmental analysis.
Results: Seventeen first-doses and 11 steady states (that is, four to six days after the first dose) were measured. Plasma 
levels varied greatly between individuals, from two- to three-fold at peak-concentrations to up to 40-fold at trough-
concentrations. Nineteen out of 21 (90%) patients had PK/PD parameters comparable to literature values. Twenty-one 
of 21 (100%) patients had appropriate duration of cefepime concentrations above the MIC (T>MIC ≥ 50%) for the 
pathogens recovered in this study (MIC ≤ 4 mg/l), but only 45 to 65% of them had appropriate coverage for potential 
pathogens with cefepime MIC ≥ 8 mg/l. Moreover, 2/21 (10%) patients with renal impairment (CLCr < 30 ml/minute) 
demonstrated accumulation of cefepime in the plasma (trough concentrations of 20 to 30 mg/l) in spite of dosage 
adjustment. Both had symptoms compatible with non-convulsive epilepsy (confusion and muscle jerks) that were not 
attributed to cefepime-toxicity until plasma levels were disclosed to the caretakers and symptoms resolved promptly 
after drug arrest.
Conclusions: These empirical results confirm the suspected risks of hidden side-effects and inappropriate PK/PD 
parameters (for pathogens with upper-limit MICs) in a population of ICU adult patients. Moreover, it identifies a safety 
and efficacy window for cefepime doses of 2 g every 12 hours in patients with a CLCr ≥ 50 ml/minute infected by 
pathogens with cefepime MICs ≤ 4 mg/l. On the other hand, prompt monitoring of cefepime plasma levels should be 
considered in case of lower CLCr or greater MICs.
Introduction
An empiric study in which the pharmacokinetics (PK) of
imipenem were prospectively monitored in intensive care
unit (ICU) children revealed wide inter-individual varia-
tions (up to four-fold at peak and >10-fold at through
concentrations) that resulted in potentially too low dos-
ages in 30% of cases [1]. Similar observations were also
made with imipenem in adult patients [2,3], suggesting
t h a t  d r u g  a d j u s t m e n t  a l g o r i t h m s  u s e d  a t  t h e  b e d s i d e
might not be always accurate in unstable ICU patients,
and that drug monitoring should be used more often [1].
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The present report describes a similar quality assess-
ment study in which the PK of cefepime was monitored in
ICU adult patients. As in the children's study alluded to
above [1], PK results were not disclosed to the caretakers
unless clinical problems were suspected to be associated
with inappropriate drug dosages. This observation is
timely in light of two meta-analyses that reported an
increased mortality (risk ratio 1.26 (95% CI 1.08 to 1.49))
in patients treated for severe infection with cefepime, as
compared to patients treated with other beta-lactams
[4,5]. Moreover, Bhat et al. [6] observed that bacteremia
due to gram-negative pathogens with minimal inhibitory
concentrations (MICs) of cefepime in the highest range of
susceptibility (that is, 8 mg/l) or above [7] were associated
with an increased mortality in patients treated with
cefepime than in those treated with other antibacterials.
Alarmed by these reports, the Food and Drug Adminis-
tration (FDA) completed a complementary meta-analysis
of 88 comparative studies (including the 38 reported by
Yahav et al) totalizing 9,467 cefepime-treated patients [8].
This analysis did not confirm a higher overall mortality
related to cefepime. Nevertheless, in the absence of drug
monitoring, the excess mortality or treatment failures
reported in specific studies [4-6] could be related to
untoward overdosing or underdosing of cefepime in
unstable patients.
Ideal dosing of cefepime should obey pharmacokinetic/
pharmacodynamic (PK/PD) population kinetics that help
adjust drug dosing to the most appropriate PK/PD profile
against target organisms [9-14]. This corresponds to a
period of drug concentration above the MIC (T>MIC) of
>40% to 60% for beta-lactams in general [15-20] and
≥50% for cefepime [19,20]. However, whether these goals
are reached in the empiric day-to-day clinical setting is
uncertain, especially in unstable ICU patients. The pres-
ent work examined these issues in 21 consecutive ICU
adult patients treated with cefepime. Individual PKs were
prospectively determined following a similar study design
as for imipenem in children [1]. The results further
strengthen the need for antibiotic monitoring in compli-
cated clinical situations.
Materials and methods
Experimental design
The Centre Hospitalier Universitaire Vaudois (CHUV) is
a 1,400-bed tertiary teaching hospital encompassing all
medical and surgical disciplines including organ grafts
and burn patients. Its ICU is a mixed medico-surgical
facility of 32 beds with a rate of admissions of approxi-
mately 2,600 patients per year. The study was aimed at
following the natural PK profiles of cefepime in ICU adult
patients, in a setting where beta-lactam monitoring was
not routinely performed. It followed a similar protocol as
in our former study of imipenem PK in the pediatric ICU
[1]. In brief, all consecutive adult patients (≥18 years old)
entering the ICU and prescribed cefepime (Bristol-Myers
Squibb AG, Baar, Switzerland) by the caretakers were
prospectively enrolled. All drug dosages and dosing-
adjustments were decided by them, based on daily clini-
cal and laboratory assessments. Patients were excluded if
they were allergic to beta-lactams, had been treated with
cefepime within the last 15 days, or were requiring dialy-
sis at the time of inclusion. The results of cefepime moni-
toring were not disclosed to the caretakers until the end
of the study, unless the caretakers or the principal investi-
gators (TMC and PM) suspected clinical problems that
might be associated with inappropriate drug concentra-
tions [1]. The study aimed at collecting a total of 20
patients. The protocol was accepted by the local ethic
committee, and written consent was obtained from the
patient or from her or his legal representative.
Cefepime dosage in the ICU is 2 g every 12 h in patients
with creatinine clearance (CLCr) ≥50 ml/minute, and 2 g
every 24 h or more in patients with CLCr < 50 ml/minute.
CLCr  was calculated by the Cockcroft-Gault equation
[21]. CLCr values reported herein are only those measured
concomitantly to the determination of cefepime PKs. The
drug was infused over 30 minutes via an intravenous line.
PK analyses were performed at the first-dose and/or at
steady state, that is, between Days 4 and 6 after treatment
onset. Blood samples were drawn from a site remote from
the drug administration line. In patients receiving the
drug every 12 h, samples were collected just before drug
administration, and at 30 minutes, 45 minutes, 1.5, 2.5, 4,
8 and 12 h after the beginning of drug infusion. In
patients receiving the drug at longer intervals, in case of
drug adaptation, blood sampling was made.
Determination of cefepime concentrations in the plasma
Cefepime titration was performed as reported in a previ-
ous work [22]. Accordingly, to prevent ex-vivo drug deg-
radation, blood samples were immediately chilled,
centrifuged, and stored at -80°C until dosage was per-
formed. All subsequent processes were performed at 4°C,
including automatic injection by a refrigerated autosam-
pler (Peltier cooler; Labsource, Reinach, Switzerland).
Briefly, the procedure included initial extraction by pro-
tein precipitation, followed by reversed phase chroma-
tography using 0.2 M Borate-Methanol (93%/7% vol/vol)
mobile phase and integration of the 260 nm absorption
signals. Calibration standards from 0.5 to 200 mg/l were
prepared in healthy volunteer's plasma with cefepime
provided by Bristol-Myers-Squibb AG (Sermoneta, Italy).
Assay was carried out with a HPLC Merck-Hitachi LaCh-
rom system (Hitachi Instruments, Ichige Hitachinaka,
Japan), and a LC18 150 × 4.6 mm column (Supelco, Belle-
fonte, PA, USA). More details on the method have already
been published elsewhere [22]. Its limit of quantification
is of 0.5 mg/l and the intra and inter run coefficients of
variation are below or at 10.3%.Chapuis et al. Critical Care 2010, 14:R51
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PK parameters
Calculated PK parameters included the terminal slope of
cefepime elimination from the plasma (Kβ), the area
under the curve of cefepime plasma concentrations
(AUC; 0 to 12 h), the area under the first moment curve
(AUMC), the terminal half-life of cefepime in the plasma
(T1/2β  = log 2/Kβ) ,  t h e  m e a n  r e s i d e n t  t i m e  ( M R T  =
AUMC/AUC), the systemic clearance (CLCEF  = dose/
AUC), and the initial and steady state volumes of distri-
bution (Vβ = CLCEF/Kβ and Vss = CLCEF × MRT, respec-
tively). For the seven-paired kinetics, comparisons
between the first-dose PK and the steady-state PK were
done by the Wilcoxon matched pairs test.
Clinical and laboratory parameters, and PK/PD analyses
Characteristics of the patients are presented in Table 1. In
addition, several clinical and biological variables were
recorded daily during the ICU stay, including weight
(using beds with weight assessment function), hemody-
namic parameters (heart rate, mean blood pressure, cen-
tral venous pressure), SAPS II score (Simplified Acute
Physiology Score) [23], serum creatinine concentrations,
creatinine clearance, urea, plasma proteins, serum albu-
min concentrations, blood lactate, pH, pCO2, HCO3,
plasma sodium and potassium, aspartate aminotrans-
ferase (ALAT), alanine aminotransferase (ASAT), pro-
thrombin time (PT), and hemoglobin. Throughout the
PK determination period, hemodynamic parameters
were recorded hourly for mean computation. Among
clinical and laboratory parameters, those having a signifi-
cant Pearson's correlation coefficient with any PK param-
eters were then selected for a stepwise multiple
regression as predictive variable for the concerned PK
parameters.
Presumed pathogens were identified at the central
microbiology laboratory of the hospital and MICs of
cefepime were determined by the E-test (AB Biodisk,
Solna, Sweden). The T>MIC period is one of the most per-
tinent parameters predicting beta-lactam efficacy [15-
20]. Therefore, this PK/PD parameter was computed for
any kinetics provided by this study, using the cefepime
MIC susceptibility breakpoints recommended by the
Clinical and Laboratory Standards Institute (CLSI) (that
is, ≤8 mg/l for Enterobacteriaceae, Pseudomonas aerugi-
nosa and Staphylococcus aureus, ≤2 mg/l for Haemophi-
lus  spp. and ≤1 mg/l or lower for Streptococcus
pneumoniae and other streptococci) [7].
Evaluation endpoints
The primary endpoints were the appropriateness of the
PK/PD profiles in terms of T>MIC regarding the recom-
mended cefepime MIC breakpoints [7], as well as clini-
cally-detected toxicity. The secondary endpoint was the
fact that patients could be discharged from the ICU and
eventually leave the hospital. On the other hand, treat-
ment success was not a formal endpoint, as the study pro-
tocol was not designed to evaluate cefepime efficacy
strico sensu.  C e f e p i m e  w a s  m o s t l y  u s e d  a s  f i r s t - l i n e
empiric treatment, and caretakers were free to switch to
more standard therapy after receiving the results of
microbial identification and susceptibility tests.
Results
Patient characteristics
Ten females and 11 males (median age 55.1 years, range
21.8 to 81.2) entered the study between 1 April and 30
September 2001. All consecutive eligible patients were
included, and no patients were excluded after entry.
Demographic details and laboratory features are pre-
sented in Table 1. Only patients with clinical and radio-
logical features compatible with nosocomial pneumonia
(as defined by onset of ≥48 h after hospitalization) were
included. This bias toward nosocomial pneumonia is
likely to result from the empiric nature of the study.
Indeed, consecutive patients were included by the care-
takers, who preferentially used cefepime monotherapy for
empiric treatment of nosocomial pneumonia (we have
notoriously few methicillin-resistant Staphylococcus
aureus in our institution), while empirical treatment of
other severe infections, mostly intra-abdominal, involves
beta-lactams with anti-anaerobe activities (that is, pen-
ems or penams) sometimes combined with other drugs.
Presumed bacterial pathogens cultured from bronchiolo-
alveolar lavage were identified in 10/21 (47%) patients.
They were all susceptible to cefepime according to the
standard MIC cut-off values (Table 1) [7].
Cefepime PK profiles
Seventeen first-dose and 11 steady-state PK profiles were
determined, among which both profiles were obtained in
seven patients. Eleven patients had only first-dose PK
determinations because they had already left the ICU by
the time steady-state measurements should have been
performed (that is, four to six days after treatment initia-
tion). Conversely, four patients had only a steady-state
measurement because they gave their written consent
after the first dose had already been administered. The 12
h administration schedule was pursued in 19 patients and
adapted in two patients with CLCr <50 ml/minute (Figure
1). Figure 1 depicts the kinetics of cefepime concentra-
t i o n s  i n  t h e  p l a s m a  v e r s u s  t i m e  a t  t h e  f i r s t - d o s e  ( l e f t
panel) and at steady-state (right panel), respectively.
Cefepime concentrations varied by two- to three-fold at
peak levels and up to 40-fold at trough levels (Figure 1
and Table 2). The majority of patients (that is, 13/17 or
76% at first dose and 9/11 or 81% at steady state) had
trough levels ≤10 mg/l. On the other hand, four patientsChapuis et al. Critical Care 2010, 14:R51
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Table 1: Clinical and microbiological features of the study population (10 females and 11 males; median age 55.1 years, 
range 21.8 to 81.2)
Reason for ICU 
admission
Underlying disease SAPS II score Weight
(Kg)
ClCr Presumed 
pathogens
MIC
(mg/l)
Cardiovascular 
surgery 1
Coronary artery disease 38 75 17.8
Multiple trauma Bipolar disorder 33 75 139.3 E. coli 0.024
Thoracic surgery 2 Non-specific interstitial 
pneumonia
33 85 126.6
Abdominal 
surgery 3
Abdominal aortic aneurysms 26 75 51
Multiple trauma Chronic obstructive pulmonary 
disease
23 86 63.4 S. aureus 2
Abdominal 
surgery
Abdominal aortic aneurysms 32 85 32.9
Cardiovascular 
surgery
Aortic stenosis 47 63 62.2
Acute respiratory 
failure 4
Obesity stage II 24 120 135.5 S. pneumoniae 0.75
Neurosurgery Cerebral arterio-venous 
malformation
50 53 166.9 E. coli 0.04
Cardiovascular 
surgery
Myeloproliferative disorder 52 65 79.6 S. pneumoniae 0.047
Multiple trauma None 42 70 133.5 P. aeruginosa 4
Cardiovascular 
surgery
Aortic bicuspidy 9 68 101.9
Acute respiratory 
failure 1
Coronary artery disease 51 60 12
Neurosurgery None 23 40 161 P. aeruginosa 4
Multiple trauma Diabetes mellitus 22 58 92.1
Cardiovascular 
surgery
Coronary artery disease 24 78 59.8
Acute respiratory 
failure 4
Myeloproliferative disorder 69 52 95.5 S. pneumoniae 1
Cardiovascular 
surgery
Coronary artery disease 33 47 115.1
Multiple trauma None 24 62 142.1
Ear-nose and 
throat surgery
Pharynx carcinoma 43 60 87.7
Neurosurgery High blood pressure 58 100 121.8 H. influenzae 1
ClCr, creatinine clearance at inclusion, as determined by the Cockcroft-Gault equation; E. coli, Escherichia coli; H. influenza, Haemophilus influenza; 
MIC, minimal inhibitory concentration; P. aeruginosa, Pseudomonas aeruginosa; S. aureus, Staphylococcus aureus;S. pneumonia, Streptococcus 
pneumoniae;
1Patients who developed drug accumulation and symptoms compatible with neurological toxicity.
2Patient suffering a further episode of bronchoaspiration; switched to amoxicillin-clavulanate during follow-up.
3Patient died eight days after leaving the ICU from multiorgan failure. Autopsy revealed an ischemic colitis with intra-abdominal steatonecrosis. 
Patient was also treated with metronidazole for the presence of Clostridium difficile in stool cultures.
4Patients eventually switched to levofloxacin as a treatment of choice of penicillin intermediate-resistant Streptococcus pneumoniae.Chapuis et al. Critical Care 2010, 14:R51
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clustered above this limit at the first dose, and two
patients with altered renal function remained above this
value at steady state, in spite of increasing the intervals of
drug administration to 24 h and 36 h, respectively (right
panel of Figure 1). These are the two patients who devel-
oped untoward neurological side effects.
PK parameters were stable in most patients, with the
notorious exception of the two patients with altered renal
function (CLCr  = 19 and 12 ml/minute, respectively).
Table 2 shows that patients with conserved renal function
(that is, a CLCr ≥50 ml/minute) had relatively comparable
PK parameters as compared to those previously reported
in healthy volunteers or burn patients. The main differ-
ence in our cohort was a greater T1/2β (h) and a parallel
increased mean residence time (MRT).
Factors influencing PK profiles
To further dwell on factors influencing cefepime kinetics
we attempted to match clinical and laboratory co-vari-
ables with specific PK parameters. Some associations
w e r e  s t r a i g h t f o r w a r d ,  s u c h  a s  t h e  d i r e c t  c o r r e l a t i o n
between ClCr and the steepness of the slope of elimination
of cefepime from the plasma (that is, the terminal slope of
cefepime clearance, or Kβ, which follows the steeper slope
of initial rapid drug distribution, or Kα) (Figure 2A, B),
and between hemodilution and volume of distribution
(Vβ) (Figure 2C). These are also the parameters most
likely to be taken into account for drug dosing adjustment
by clinicians.
Table 3 presents some of these parameters. Although
several are easily associated with hemodynamic condi-
tions, others could be more intricately involved in drug
elimination, as exemplified by the reported pH-depen-
dent, plasma-dependent, and temperature-dependent
degradation of cefepime [22,24,25]. In this line, both the
pCO2 and the HCO3 were significantly associated with
decreased drug half-life and mean resident time. Thus, in
complex clinical situations the PK profiles might be influ-
enced by individual physiopathological variables that are
not taken into account in standard algorithms for adjust-
ment of drug dosages.
Side effects
The protocol was not aimed at detecting specific side
effects of cefepime therapy. Therefore, possible related
side effects were left on the appreciation of the caretak-
ers, based on daily complete clinical and laboratory
assessments. No untoward side effects were attributed to
cefepime by the caretakers at first. Yet the two (10%)
patients with high concentrations of cefepime in the
plasma (highest concentrations in right panel in Figure 1)
presented episodes of confusion and flapping tremor
compatible with metabolic encephalopathy. Both had
altered renal functions and had been subjected to dosing
adjustment (2 g of cefepime q 24 h and 36 h for the
patients with CLCr of 19 and 12 ml/minute, respectively).
Yet, this dosage adjustment was insufficient and they had
nevertheless high plasma levels. The accumulation of
cefepime in the plasma concentrations was disclosed to
the medical staff, and both patients recovered within 24 h
of treatment arrest.
Pharmacodynamic profiles and clinical outcome
Optimal beta-lactam efficacy requires T>MIC of >60% to
70% for Enterobacteriaceae and streptococci, and 40 to
50% for Staphylococcus aureus [15-19,26]. For certain
beta-lactams including cefepime, a lower limit of 50% was
also suggested [19,20]. Table 4 presents the T>MIC of the
present patient population as determined for cefepime
MICs of 4 and 8 mg/l, respectively. At the dosage used
herein (that is, 2 g q 12 h in patients with CLCr ≥50 ml/
minute) all patients had T>MIC  values above 50% for
cefepime MIC of ≤ 4 mg/ml. Thus, the theoretical PD
coverage was appropriate for all the presumed pathogens
recovered in this study (cefepime MIC ≤4 mg/l). All
patients in this study were discharged from the ICU with-
out antibiotic treatment failure regarding the indication
of cefepime treatment, and all except one (Table 1) could
eventually leave the hospital. On the other hand, when
increasing the cefepime MIC cut-off to 8 mg/ml, T>MIC
decreased to ≤67% at the first dose and <44% at steady
state, indicating that the dosage would be inadequate in a
substantial number of patients infected with Gram-nega-
tive pathogens with such borderline susceptibilities, as
suggested by Bhat et al. [6].
Discussion
The present empirical study confirms the great inter-
individual variability of cefepime PK in the clinical set-
ting, as reported with cefepime and imipenem by others
[1,2,27,28]. Moreover, it underlines the difficulty of bed-
Figure 1 Pharmacokinetic profile of cefepime. Concentration of 
cefepime versus time determined in the plasmas of 21 consecutive pa-
tients as determined at the first dose (left panel; 17 individual PK pro-
files) or at steady state (right panel; 11 individual PK profiles). Colors 
identify individual patients. 
  
  
  
  
  





	















	

 



  

	

 
	


!

"

#

$








Chapuis et al. Critical Care 2010, 14:R51
http://ccforum.com/content/14/2/R51
Page 6 of 10
side prediction of cefepime PK, based on standard drug
adjustment algorithms, including calculated CLCr. In the
present series, this resulted in extreme cefepime concen-
trations in the plasma from rather low values (trough
cefepime concentrations below 4 mg/l in ca 50% of the
patients) (Figure 1) to unpredicted toxic values in two
other patients with renal impairment.
A major parameter for cefepime drug adjustment is
CLCr, which is often calculated by the classical Cockcroft-
Gault equation [21]. However, calculated clearance may
be subject to errors because it does not take into account
features such as muscular mass and turnover, which may
influence creatinine concentrations in the serum [29].
Therefore, biases in calculated CLCr could be one poten-
tial explanation for the inter-individual PK variability
observed. Nevertheless, although the Cockcroft-Gault
equation may suffer from inaccuracies, the calculated
CLCr values correlated very well with cefepime clearance,
as indicated in Figure 2. Additionally, we also tentatively
calculated CLCr values using the MDRD (Modification of
Diet in Renal Disease) method [30], but the results were
quite concordant with the values presented herein (data
not presented). Hence, some of the variations might be
due to other factors.
For instance, some patients had increased CLCr as pre-
viously reported (>120 ml/minute, Figure 2) [31] and
might have benefited from increasing drug dosages.
Alternatively, additional more intricate parameters pre-
Table 2: Pharmacokinetic parameters and comparison with previous literature using cefepime dosage of 2 g q 12 h.
Parameters and time 
of calculation
Mean reported values ± SD
Present study Barbhaiya et al. 3[45] Sampol et al.4[50] Bonapace et al.4[44]
First dose (17 patients)
T1/2β (h) 4.03 ± 3.19 NS 2.45 ± 0.56 2.8 ± 0.6
CMax (mg/l) 1 105 ± 22 132 ± 21 NS 102 ± 15 5
CMin (mg/l)1 7.6 ± 12 NS NS NS
AUC (mg.h/liter) 370 ± 360 268 ± 27 217 ± 34 224 ± 59
MRT (h) 5.1 ± 4.64 2.56 ± 0.31 NS NS
Clearance (liter/
h.kg) 1,2
0.130 ± 0.077 NS 0.152 ± 0.025 0.1 ± 0.03
Vβ (liter/kg) 0.513 ± 0.180 NS NS NS
VSS (liter/kg) 0.413 ± 0.118 NS 0.36 ± 0.1 0.43 ± 0.1
Steady state (11 
patients)
T1/2β (h) 4.33 ± 4.32 Not available 2.62 ± 0.53 Not available
CMax (mg/l) 1 97 ± 8 NS
CMin (mg/l)1 2.68 ± 3.06 NS
AUC (mg.h/liter)1 226 ± 107 262 ± 57
MRT (h) 5.3 ± 5.9 NS
Clearance (liter/
h.kg)
0.131 ± 0.084 0.133 ± 0.029
Vβ (liter/kg) 0.513 ± 0.180 NS
VSS (liter/kg) 0.413 ± 0.118 0.35 ± 0.1
CMax and CMIN, maximal and minimal plasma concentrations at the end of drug infusion and just before the next infusion, respectively; AUC, 
area under the curve; MRT, mean residence time; NS, not specified; T1/2β, terminal plasma half-life; Vβ, initial volume of distribution; VSS, 
volume of distribution at steady state
1only patients with 2 g q 12 h (without two cases with dose adjustment at steady state)
2extrapolated to infinity for the first PK
3in normal volunteers
4in burn patientsChapuis et al. Critical Care 2010, 14:R51
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sented in Table 3 might also interfere. Among these, some
relations were expected, such as the direct correlation
between ClCr and cefepime elimination, whereas others
were less obvious, such as the direct correlation between
the concentration of plasma albumin and Kβ (Figure 2D).
Depending on the circumstances, high plasma albumin
may be associated either with dehydration, which could
result in poor renal perfusion and decreased cefepime
clearance, or with good cardiovascular performance and
good cefepime clearance, which was likely to be the case
herein.
Other parameters for initial dosing are weight and gen-
der, which might call less attention by the caretakers in
adult than in pediatric medicine. However extreme
weights in our series varied by three times (Table 1) and
were not likely to explain the up to 40-times difference in
drug levels observed. Moreover, similar variations were
observed in other PK studies [2,3], and especially in chil-
dren, where weight is a prime consideration in drug dos-
ing decision [1]. Taken together, the extreme variations
observed are likely to result from intricate interactions
between multiple factors, which are by no way simple to
integrate in the bedside decision process.
Most patients with a preserved renal function had sta-
ble individual PK profiles over time in spite of a wide
range of CLCr values ranging from 160 to 53 ml/minute
(Figure 2), and the fact that no drug adjustments were
performed. In contrast, drug accumulation and toxicity
was observed in two patients with renal impairment
(CLCr < 50 ml/minute), in spite of drug adjustment. This
is potentially important because caretakers did not attri-
bute neuropsychological alterations, which may be multi-
factorial in ICU conditions, to drug toxicity until the high
concentrations of cefepime were disclosed to them and
the symptoms resolved promptly after treatment arrest.
Moreover, there is a lack of information in the literature
regarding the threshold of cefepime plasma levels pre-
dicting neurotoxicity. Indeed, out of 35 patients with
cefepime-induced neurological complications reported in
10 studies (excluding reviews and chronic dialysis
patients) [27,28,32-39], the concentrations of cefepime
were determined in only one case (in the plasma and the
CSF) and were quite high, that is, 284 mg/l and 18 mg/l,
respectively [28]. Besides, only one recent study in neu-
tropenic patients with mild renal failure indicated that
trough plasma concentrations of cefepime above 22 mg/l
w e r e  l i k e l y  t o  b e  a s s o c i a t e d  w i t h  e n c e p h a l o p a t h y  [ 4 0 ] .
The main constant over all the reported cases is the asso-
ciation of neurotoxicity with renal impairment. While
renal impairment implies possible drug accumulation, it
might also potentiate the effect of additional neurotoxic
factors, including factors related to the patient, or maybe
the C-3' substituent N-methylpyrrolidine metabolite of
cefepime, which may accumulate in the case of renal fail-
ure [25,41]. Thus, the threshold of toxicity might be
patient-dependent. On the other hand, most studies
examining the PK produced by 2 g of the drug adminis-
tered intravenously or intramuscularly to healthy volun-
teers or patients without renal failure report trough
cefepime concentrations in the plasma ≤10 mg/l in
[9,11,42-46], which was also the case herein. Therefore a
safe assumption is that trough concentrations of >10 mg/l
of cefepime should alert the clinician on the risk of neu-
rotoxicity in susceptible patients, and concentrations of
>20 mg/l should probably be avoided.
On the other extreme, too low dosages may result in
treatment failures, at least as predicted by PK/PD studies
[15-19,26]. Postulating that T>MIC measured is pertinent
to predict clinical outcome, then all of our patients had
appropriate coverage of cefepime (T>MIC  ≥ 50%) as
recently proposed [19,20] for the presumed bacterial
pathogens recovered herein (MIC ≤ 4 mg/l) (Table 4). On
the other hand, if one postulates an MIC of 8 mg/l, which
was associated with treatment failures in patients with
bacteremia due to Gram negative pathogens [6], then
close to 50% of the patients would have had an inappro-
priate coverage (T>MIC > 50%). This is of particular con-
cern when considering problematic pathogens such as
those producing extended-spectrum beta-lactamases, or
P. aeruginosa and  Acinetobacter  spp., which may have
high cefepime MICs (≥8 mg/l) and pose major therapeu-
tic challenges, and if one takes into account that up to
Figure 2 Significant correlations between physiological and 
pharmacokinetic parameters. Cefepime elimination closely correlat-
ed with creatinine clearance (panels A and B), as abundantly described 
[15-20]. In addition, more intricate parameters also showed indepen-
dent negative and positive correlations with drug elimination, as for in-
stance the concentrations of hemoglobin (panel C) and plasma 
albumin (panel D). Corresponding coefficients of correlations (r values) 
are indicated. Additional correlations are presented in Table 3.
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20% of the total drug is bound to serum proteins [47,48].
Moreover, in addition to pure MIC concerns, a recent
study identified P. aeruginosa infection, mechanical ven-
tilation, and neutropenia as independent risk factors for
cefepime treatment failure [49]. Higher cefepime doses
w e r e  p r o p o s e d  t o  o v e r c o m e  s o m e  o f  t h e s e  i s s u e s  ( f o r
example, 2 g q 8 h) [9], but high doses may also increase
the risk of neurological side effects. Hence, adjusting dos-
age on the basis of drug monitoring is reasonable in such
cases.
Conclusions
Taken together, these results of drug monitoring inde-
pendently validate the population kinetics of cefepime
elaborated by others [9-14]. Moreover, they show that
empirical drug dosing following standard drug adjust-
ment algorithms in the ICU is not accurate enough to
prevent extreme PK deviations, which might be one or
the possible explanations for the toxicity and treatment
failure problems reported by Yahav et al. [4] and Bhat et
al. [6]. Eventually, they indicate that 2 g of cefepime q 12 h
Table 3: Combined two-by-two correlations and multiple regression between clinical and laboratory parameters, and PK 
values.
Clinical and 
laboratory 
parameters
Pharmacokinetic parameters 1,2(number of data points)
Kβ T1/2β MRTiv CLCEF Vβ VSS
Weight 0.08 -0.05 -0.04 -0.34 -0.42** -0.47**
(28) (28) (28) (28) (28) (28)
Age -0.65** 0.58* 0.61* -0.75** -0.50** -0.34
(28) (28) (28) (28) (28) (28)
Proteins 0.52* -0.27 -0.28 0.24 -0.13 -0.29
(26) (26) (26) (26) (26) (26)
Albumin 0.63* -0.31 -0.32 0.21 -0.27 -0.43**
(26) (26) (26) (26) (26) (26)
Hemoglobin 0.07 0.06 0.07 -0.42** -0.58** -0.59**
(28) (28) (28) (28) (28) (28)
Na+ -0.11 0.01 -0.01 0.17 0.38 0.38
(28) (28) (28) (28) (28) (28)
Creatinine -0.78** 0.91* 0.91* -0.69** -0.31 -0.19
(27) (27) (27) (27) (27) (27)
CLCr 0.79* -0.81** -0.82** 0.88* 0.51* 0.35
(27) (27) (27) (27) (27) (27)
pCO2 0.28 -0.41 -0.42** 0.03 -0.14 -0.20
(23) (23) (23) (23) (23) (23)
HCO3 0.33 -0.42** -0.41 -0.05 -0.27 -0.33
(23) (23) (23) (23) (23) (23)
Cefepime dose 
(mg/kg)
0.19 -0.17 -0.17 0.57* 0.51* 0.53*
(28) (28) (28) (28) (28) (28)
1Significant Pearson's coefficients with P < 0.05 are highlighted by asterisk. One asterisk indicates positive (direct) correlations and two 
asterisk indicate negative (inverse) correlations.
2For each PK parameters, the most pertinent physiological parameters according to the result of the two by two correlations were included 
as independent variable in a forward stepwise multiple regression. Creatinine serum levels were excluded from the analysis (in spite of a 
significant correlation with some pK parameters) because of a non-normal (bimodal) distribution. Creatinine clearance, which shares similar 
biological information, was more regularly distributed. Remaining primary predictive variable (P < 0.05) after this procedure are marked in 
bold italic font in the table.Chapuis et al. Critical Care 2010, 14:R51
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is safe and effective for patients with CLCr ≥ 50 ml/minute
and against pathogens with cefepime MICs ≤ 4 mg/l, but
that drug monitoring should be considered in any condi-
tions falling outside these limits.
Key messages
• 2 g of cefepime every 12 h was safe and appropriate
for patients with CLCr ≥50 ml/min pathogens with
cefepime MICs ≤4 mg/l.
• However, this dosage was too low up to 50% of more
o f  p a t i e n t s  i n f e c t e d  w i t h  m i c r o b e s  w i t h  g r e a t e r
cefepime MICs (≥8 mg/l).
• Moreover, cefepime accumulation and neurological
toxicity (non-convulsive epilepsy) occurred in two
patients with CLCr <50 ml/minute, in spite of drug
dosage adjustment.
• Monitoring of cefepime plasma levels is warranted
in patients with CLCr <50 ml/minute and infection
due to pathogens with cefepime MICs ≥8 mg/l.
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